Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxifluridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.54 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | PYGM | P11217 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | TK2 | O00142 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxifluridine SCHEMBL28690558 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL10079621 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL4932137 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL14291576 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL14564897 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL12932255 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL98005 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL8095 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL15060572 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| Doxifluridine SCHEMBL13300971 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2MAPTTSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 57837 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748859-A2 | CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF | The Regents of the University of California (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4743490-A1 | HUMANIZED ANTI-CD7 ANTIBODY | Christian-Albrechts-Universität zu Kiel (DE) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| CN-122028934-A | Combination of CLDN18_2 antibody and chemotherapeutic drug and application thereof | 江苏奥赛康生物医药有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260115305-A1 | LINKERS, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4727979-A2 | COMPOSITIONS AND METHODS FOR TARGETING EXTRACELLULAR DNA | Caris Science, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| EP-0454773-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | Bundgaard, Hans (DK) | 1991-11-06 | — | — | EP | claimed |
| EP-0443028-A1 | NON-INJECTION CARCINOSTATIC AGENT FOR SUPPRESSING OCCURRENCE OF INFLAMMATION DUE TO 5-FLUOROURACIL AND METHOD FOR CURING CANCER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| WO-1990008128-A1 | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS | BUNDGAARD HANS (DK) | 1990-07-26 | — | — | WO | claimed |
| EP-0189755-B1 | PHARMACEUTICAL COMPOSITION | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-03 | — | — | EP | claimed |
| EP-0189755-A1 | Pharmaceutical composition | F. HOFFMANN-LA ROCHE AG (CH) | 1986-08-06 | — | — | EP | claimed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | claimed |
| EP-0021231-B1 | PROCESS FOR THE PREPARATION OF 5'-DEOXY-5-FLUORO URIDINE AND INTERMEDIATES IN THIS PROCESS | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-10-05 | — | — | EP | claimed |
| EP-0021231-A2 | Process for the preparation of 5'-deoxy-5-fluoro uridine and intermediates in this process | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-01-07 | — | — | EP | claimed |
| US-4071680-A | ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1978-01-31 | — | — | US | claimed |